Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,161–1,170 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1161
- Medicine slug
- paliperidone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
28%
- Numeric value
- 28
- Unit
- %
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5492459-e0a2-4c16-9fff-c886e0b4c700 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8e5b26-b9e4-4704-921b-3c3c0d159916 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following INVEGA administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d80cc0-596e-49b9-8216-34e7b01e2df2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cdf6fb-d59f-4231-bd21-c8435df5930d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71985eb4-07df-41c9-8b9a-85f39e92b7d0 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:528a962a-4924-4c48-93ce-6ab1f019e52c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dc3a9b2-2edf-4fa2-a949-459b4218e763 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13d3678-a861-42ba-be44-0d89f1b66ef3 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5589ec69-c49c-44a7-9561-bbffeb918d1f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Absorption and Distribution The absolute oral bioavailability of paliperidone following paliperidone administration is 28%.
Projected row 1162
- Medicine slug
- paliperidone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
23 hours
- Numeric value
- 23
- Unit
- hours
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be30f3cc-55fb-4a74-9778-60573a7f18c6 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5492459-e0a2-4c16-9fff-c886e0b4c700 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45fc28d1-132f-413b-a407-dc90e1229ee2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:018cf3ca-bee9-23a6-e063-6394a90ad905 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8e5b26-b9e4-4704-921b-3c3c0d159916 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b269778-803b-4ce2-a8c0-636fb131d16a (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d80cc0-596e-49b9-8216-34e7b01e2df2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cdf6fb-d59f-4231-bd21-c8435df5930d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313538c9-01d3-1558-e063-6394a90aa21d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0c13f91-0232-48b0-aa13-121805b8da13 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71985eb4-07df-41c9-8b9a-85f39e92b7d0 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1745a460-5e3a-4a1f-8eb3-64bb112f47a4 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95e29f-a030-4777-a601-874500ab8e91 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5ef11c-5c22-4a8e-89dd-4740f0ebf634 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfcad42-da71-457d-b1e1-aee806642d0c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e713556e-028e-0f4c-e053-2995a90a9e9f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463db841-297f-7692-e063-6394a90a8c14 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7033e52-3df2-48e2-adda-15a57c2f148f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75e884e-1883-45d7-ac9b-4a6c63f2185e (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7472b50-fa6c-4127-a4b3-3645436274ee (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbbaa057-f587-4eb9-a0d2-463dbcd57661 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:528a962a-4924-4c48-93ce-6ab1f019e52c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dc3a9b2-2edf-4fa2-a949-459b4218e763 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13d3678-a861-42ba-be44-0d89f1b66ef3 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5589ec69-c49c-44a7-9561-bbffeb918d1f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The terminal elimination half-life of paliperidone is approximately 23 hours.
Projected row 1163
- Medicine slug
- paliperidone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
74%
- Numeric value
- 74
- Unit
- %
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be30f3cc-55fb-4a74-9778-60573a7f18c6 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5492459-e0a2-4c16-9fff-c886e0b4c700 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45fc28d1-132f-413b-a407-dc90e1229ee2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:018cf3ca-bee9-23a6-e063-6394a90ad905 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8e5b26-b9e4-4704-921b-3c3c0d159916 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b269778-803b-4ce2-a8c0-636fb131d16a (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d80cc0-596e-49b9-8216-34e7b01e2df2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cdf6fb-d59f-4231-bd21-c8435df5930d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313538c9-01d3-1558-e063-6394a90aa21d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0c13f91-0232-48b0-aa13-121805b8da13 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71985eb4-07df-41c9-8b9a-85f39e92b7d0 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1745a460-5e3a-4a1f-8eb3-64bb112f47a4 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95e29f-a030-4777-a601-874500ab8e91 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5ef11c-5c22-4a8e-89dd-4740f0ebf634 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfcad42-da71-457d-b1e1-aee806642d0c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e713556e-028e-0f4c-e053-2995a90a9e9f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463db841-297f-7692-e063-6394a90a8c14 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7033e52-3df2-48e2-adda-15a57c2f148f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75e884e-1883-45d7-ac9b-4a6c63f2185e (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7472b50-fa6c-4127-a4b3-3645436274ee (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbbaa057-f587-4eb9-a0d2-463dbcd57661 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:528a962a-4924-4c48-93ce-6ab1f019e52c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dc3a9b2-2edf-4fa2-a949-459b4218e763 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13d3678-a861-42ba-be44-0d89f1b66ef3 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5589ec69-c49c-44a7-9561-bbffeb918d1f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The plasma protein binding of racemic paliperidone is 74%.
Projected row 1164
- Medicine slug
- paliperidone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be30f3cc-55fb-4a74-9778-60573a7f18c6 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5492459-e0a2-4c16-9fff-c886e0b4c700 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45fc28d1-132f-413b-a407-dc90e1229ee2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:018cf3ca-bee9-23a6-e063-6394a90ad905 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8e5b26-b9e4-4704-921b-3c3c0d159916 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b269778-803b-4ce2-a8c0-636fb131d16a (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d80cc0-596e-49b9-8216-34e7b01e2df2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cdf6fb-d59f-4231-bd21-c8435df5930d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313538c9-01d3-1558-e063-6394a90aa21d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0c13f91-0232-48b0-aa13-121805b8da13 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71985eb4-07df-41c9-8b9a-85f39e92b7d0 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1745a460-5e3a-4a1f-8eb3-64bb112f47a4 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95e29f-a030-4777-a601-874500ab8e91 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5ef11c-5c22-4a8e-89dd-4740f0ebf634 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfcad42-da71-457d-b1e1-aee806642d0c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
The pharmacological activity of the (+)- and (-)- paliperidone enantiomers is qualitatively and quantitatively similar in vitro. 12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e713556e-028e-0f4c-e053-2995a90a9e9f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463db841-297f-7692-e063-6394a90a8c14 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7033e52-3df2-48e2-adda-15a57c2f148f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75e884e-1883-45d7-ac9b-4a6c63f2185e (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7472b50-fa6c-4127-a4b3-3645436274ee (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbbaa057-f587-4eb9-a0d2-463dbcd57661 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:528a962a-4924-4c48-93ce-6ab1f019e52c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dc3a9b2-2edf-4fa2-a949-459b4218e763 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13d3678-a861-42ba-be44-0d89f1b66ef3 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5589ec69-c49c-44a7-9561-bbffeb918d1f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (C max ) approximately 24 hours after dosing.
Projected row 1165
- Medicine slug
- paliperidone
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 25
- Source count
- 25
- Agreement rate
- 1
- Recorded readings
487 L
- Numeric value
- 487
- Unit
- L
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be30f3cc-55fb-4a74-9778-60573a7f18c6 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5492459-e0a2-4c16-9fff-c886e0b4c700 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45fc28d1-132f-413b-a407-dc90e1229ee2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:018cf3ca-bee9-23a6-e063-6394a90ad905 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b8e5b26-b9e4-4704-921b-3c3c0d159916 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b269778-803b-4ce2-a8c0-636fb131d16a (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6d80cc0-596e-49b9-8216-34e7b01e2df2 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85cdf6fb-d59f-4231-bd21-c8435df5930d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:313538c9-01d3-1558-e063-6394a90aa21d (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0c13f91-0232-48b0-aa13-121805b8da13 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71985eb4-07df-41c9-8b9a-85f39e92b7d0 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1745a460-5e3a-4a1f-8eb3-64bb112f47a4 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de95e29f-a030-4777-a601-874500ab8e91 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff5ef11c-5c22-4a8e-89dd-4740f0ebf634 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1cfcad42-da71-457d-b1e1-aee806642d0c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e713556e-028e-0f4c-e053-2995a90a9e9f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:463db841-297f-7692-e063-6394a90a8c14 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7033e52-3df2-48e2-adda-15a57c2f148f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f75e884e-1883-45d7-ac9b-4a6c63f2185e (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7472b50-fa6c-4127-a4b3-3645436274ee (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bbbaa057-f587-4eb9-a0d2-463dbcd57661 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:528a962a-4924-4c48-93ce-6ab1f019e52c (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0dc3a9b2-2edf-4fa2-a949-459b4218e763 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13d3678-a861-42ba-be44-0d89f1b66ef3 (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5589ec69-c49c-44a7-9561-bbffeb918d1f (opens source in a new tab)
Paliperidone label
Version not recorded · Effective date not recorded
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L.
Projected row 1166
- Medicine slug
- palonosetron
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 0.842105
- Recorded readings
40 hours
- Numeric value
- 40
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:903d7aba-277e-6d28-4fee-fd2d605ab6a9 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9132366b-b808-46c9-b167-c1900bc116b3 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911783eb-91a8-4ef4-bd6f-809211e207d6 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af600d1-0ab1-41c5-af2f-9dc24cf3c90e (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a781796-bb74-4c5f-8d26-9ce520b818f7 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e60d03d-eae6-4924-a507-e77ea077c1ab (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bfb3984-2b47-4e06-9bbb-d055ebc376c8 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42e2d437-0712-4e9c-9c2a-00093c406d62 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aff1505c-8d34-46e6-9559-c5b112887875 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3bfe3d-75c8-42eb-84be-570f8e251fdd (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:633abdc2-a942-4eb2-a0f8-f9f4e727211e (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b93fae8e-2b76-421e-95bc-ba08c211a7ea (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11bb07b2-6530-45ab-a916-ba9dd3107fc3 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6f6f94-1ca7-481e-9909-b19ae64e80c2 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Mean terminal elimination half-life is approximately 40 hours.
30 hours
- Numeric value
- 30
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:991b8452-852c-c55c-7b1b-e97c4964777a (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
The median half-life was 30 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:689c953c-2120-2546-67a4-22bb34ba3330 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
The median half-life was 30 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.
29.5 hours
- Numeric value
- 29.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37e7ef89-fd77-44e0-9271-ae91f8822603 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 mcg/kg.
Projected row 1167
- Medicine slug
- palonosetron
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
8.3 ± 2.5 L/kg
- Numeric value
- 8.3
- Unit
- L/kg
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:903d7aba-277e-6d28-4fee-fd2d605ab6a9 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb2be46a-56f7-48b6-bb05-3c6b12c8b1ea (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9132366b-b808-46c9-b167-c1900bc116b3 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:911783eb-91a8-4ef4-bd6f-809211e207d6 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:991b8452-852c-c55c-7b1b-e97c4964777a (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4af600d1-0ab1-41c5-af2f-9dc24cf3c90e (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a781796-bb74-4c5f-8d26-9ce520b818f7 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e60d03d-eae6-4924-a507-e77ea077c1ab (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:689c953c-2120-2546-67a4-22bb34ba3330 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bfb3984-2b47-4e06-9bbb-d055ebc376c8 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42e2d437-0712-4e9c-9c2a-00093c406d62 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37e7ef89-fd77-44e0-9271-ae91f8822603 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aff1505c-8d34-46e6-9559-c5b112887875 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f3bfe3d-75c8-42eb-84be-570f8e251fdd (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:633abdc2-a942-4eb2-a0f8-f9f4e727211e (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b93fae8e-2b76-421e-95bc-ba08c211a7ea (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11bb07b2-6530-45ab-a916-ba9dd3107fc3 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6f6f94-1ca7-481e-9909-b19ae64e80c2 (opens source in a new tab)
Palonosetron label
Version not recorded · Effective date not recorded
Distribution Palonosetron has a volume of distribution of approximately 8.3 ± 2.5 L/kg.
Projected row 1168
- Medicine slug
- pamidronate
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
28 ± 7 hours
- Numeric value
- 28
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23 (opens source in a new tab)
Pamidronate label
Version not recorded · Effective date not recorded
The mean ± SD elimination half-life is 28 ± 7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2ca033e-fa5f-4141-b702-11f8b4303da1 (opens source in a new tab)
Pamidronate label
Version not recorded · Effective date not recorded
Elimination The elimination half-life is 28 ± 7 hours (mean ± standard deviation).
Projected row 1169
- Medicine slug
- pantoprazole
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 133
- Source count
- 107
- Agreement rate
- 1
- Recorded readings
77%
- Numeric value
- 77
- Unit
- %
- Source records
- 107
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 107 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58d32be2-166e-1a64-e063-6394a90a26ea (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81696241-17d5-4d35-9e59-8c28469ffd2c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03aa46f-9eb5-4cf4-addf-745d94af8261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4494f9d0-a1c8-477f-9b4a-f65d7637d9ec (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bed1bae-519f-1bb9-e063-6294a90a795b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d212e8ec-f7ff-4727-a83e-0edc4ca7e6d1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643eb498-d916-4fb7-9281-32895575ab36 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1839b-7462-4344-b319-001a5f57d67a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1e79ad-ff52-4696-8743-523f793b29d3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f50bcb-85e5-e3f6-e063-6294a90a11ae (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8748a588-a1e5-9dfc-e053-2a95a90a846c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1680b4ed-d5b0-4fd9-b1d1-04df6a2138be (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5421ef-0875-4a04-b17d-95cca0052c83 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517d6b02-0e68-4d6b-98b3-eac0be457e6b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6faf465b-c3a3-4ae7-9e16-1ba758f6962a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d27e1fdd-e23f-0d60-e053-2a95a90a9087 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9b0d279-118b-4372-bd51-d4bad9c1cfca (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3540d01c-da0e-477e-9e90-994b96deb1d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e200326-8885-18d0-e063-6294a90aad2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed264262-21bb-1bae-e053-2995a90a8a5e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85e6d64-1ddc-4f4a-86dc-0749081a6a5f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08098cb2-c048-4640-f387-6beec4a38936 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c286e5c-2b36-422b-9f74-e8c0abb3f747 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc5197e-6b39-4415-b963-d4bbeecd7953 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17468dbf-84b6-4c53-9ad5-341350d2cfab (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56ad5b97-8e5f-48a5-b2ba-a5484b43d018 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a278de-bd16-417c-a741-81bfe0d745f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e7c1ab-3e75-1ff8-e053-2995a90a7539 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b422c5eb-9a6d-4f8c-863d-ca515ec780c2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7418f358-f536-4de6-adf0-562b4373f2e3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f2fb647-15bc-41cb-84a4-02e956e614fc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138b30cb-6b28-450e-9e7a-42576cc76545 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbec80c-b38d-122c-e054-00144ff88e88 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9f32edf-e0b9-4e96-e053-2a95a90afbc8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4136d983-75fa-9604-e063-6294a90aaac6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9fa8381-b75e-b1cd-e053-2a95a90a9883 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a1af50-a051-3e55-e053-2a95a90a9184 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5ed424-2203-482f-bb85-2c97d9c356f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:564709e8-358f-c185-4ecb-b3849c3fe59c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbab54-9f11-77bc-e063-6394a90ab449 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566b4b1-b4f5-4020-e063-6394a90a5257 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8fa326-ad75-4b6d-8832-0a2357eeca2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a6b13f-457f-4136-9541-c4adb9c3c35c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9bc288b-e84c-4e31-a769-c87a59226086 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410d5577-e50a-44f3-aaa8-fbf391a0c261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51033ddc-a11a-80fa-e063-6394a90ac54c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549da3e8-f223-2ee7-e063-6394a90a25d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0bb76bc-094a-4d61-9bb2-2226c9da4ae9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17e4a72-d6a4-4a83-a921-88af9ef028a6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd4759ac-46b5-6903-e053-2a95a90a6319 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924a80b9-de48-90c0-e053-2995a90a00e1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423dac8b-bb1e-4456-9b6e-913c028b11bc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9e3c6-d4b0-0ebe-e053-2995a90abe55 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff83f9-7039-ac26-e063-6394a90a37ce (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90963a38-f629-45a4-bddd-9e13a55fe0f7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da67e1c0-9947-957d-e053-2a95a90ad96d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a1159d3-b9fa-4026-962c-d3001002e610 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:558dc7e1-dfd5-d3d7-e063-6394a90ab9c3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14e2f3-625d-4089-a404-440b0ecf72e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff3cf6c-6f0a-4374-8b80-4e1eb1df6245 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6aae78e-308b-7072-e053-2a95a90aaa10 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1eb666a-120d-47fd-8c9f-73cef839294a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7705bf6-e473-4b9c-bb5d-57e26ffe7b97 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac1642-6cb0-6ad2-e053-2a95a90a4cbd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fc6326-cfe6-7d1c-e063-6394a90abc24 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6229247e-ee15-466e-a8ac-adcd646b738d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c983da1-a8e0-479e-8816-5d5668ea242e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f37929-a981-4ace-95e6-ae6795a797b3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f313159c-115a-4cf6-b32e-9ddc833fd51c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3ded82a-cf0d-4844-944a-75f9f9215ff0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485212d4-caee-4a55-8299-87a28d6bd8f0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6278c0-d8c0-417c-a65c-b522ff76fe44 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f711d8-b9d3-46a6-8bf9-6af1cc77003e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f408cf-1b3e-4d7a-e053-2a95a90a369f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cec41e-e98b-470a-8ba2-c31537023989 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcac4022-fea1-67c5-3331-fefcc3c440d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8eed8c-f5d0-4b90-b184-cff8d9c8fb6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5331f534-4724-52e8-e063-6394a90aa548 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58c376e-616b-4970-a375-52ff630e7f09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d03491f-20c6-4878-9741-2e21e221eff2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d51104d-b135-421f-8425-03b5772e7103 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e9c12-e39d-4b0b-bd4c-10d3e9a4cf34 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dc4321-331d-49af-976c-cfd69d0055d9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38353b9e-63bd-47e8-b7cb-b198d1e901f9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2abc159-e450-99dc-e053-2a95a90abe6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617bb464-5357-472f-8e9d-61aae5b2ebef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3277cb8-26d0-bce0-e053-2a95a90af6dd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a969c3-1144-4151-9cf3-3e9bace6a380 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd035d0-529c-6033-e053-6294a90abf07 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9deb251-96d3-5f96-e053-2a95a90a0792 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637d90b-b268-4a5f-ab5b-885f2d5f0d4b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1cbf26-d379-4315-8732-3939968f32c0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aa55ec-5e0e-3a58-e053-2a95a90abe4f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f38a6df2-1dd4-48bf-9ec4-1113ce492e78 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f403c94d-68b7-43df-8c8e-c9fef3309cfc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff15c4f1-8869-4422-9631-dc488e09e583 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce2e97a-cd92-46b9-9444-91739bdcd526 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ba58cc-e4ef-4b82-a0f3-9583fa123a38 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f0103a-2b97-d210-6d7d-c627d60ad694 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c46140c-2399-5ca3-e063-6394a90af33b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fbf3b5-ddf4-4d3a-8b69-a0c38b3fa5e2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89a5396-1d94-c7fa-e053-2995a90a9063 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:440b9ae8-2fb8-5d35-e063-6294a90a82b6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a94a37-47c1-4dd9-9e4d-5b4a03480aa6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de419aa0-caa9-40fb-bc6d-e341c94273c7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03dea010-4bae-43ab-893e-9bbddb58062d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9daa1483-5a36-44db-9e0d-904d100da262 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Pantoprazole undergoes little first-pass metabolism, resulting in an absolute bioavailability of approximately 77%.
Projected row 1170
- Medicine slug
- pantoprazole
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 133
- Source count
- 133
- Agreement rate
- 0.789474
- Recorded readings
7 to 9 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 105
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 105 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58d32be2-166e-1a64-e063-6394a90a26ea (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81696241-17d5-4d35-9e59-8c28469ffd2c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03aa46f-9eb5-4cf4-addf-745d94af8261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4494f9d0-a1c8-477f-9b4a-f65d7637d9ec (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bed1bae-519f-1bb9-e063-6294a90a795b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d212e8ec-f7ff-4727-a83e-0edc4ca7e6d1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643eb498-d916-4fb7-9281-32895575ab36 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1839b-7462-4344-b319-001a5f57d67a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1e79ad-ff52-4696-8743-523f793b29d3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f50bcb-85e5-e3f6-e063-6294a90a11ae (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8748a588-a1e5-9dfc-e053-2a95a90a846c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1680b4ed-d5b0-4fd9-b1d1-04df6a2138be (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5421ef-0875-4a04-b17d-95cca0052c83 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517d6b02-0e68-4d6b-98b3-eac0be457e6b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6faf465b-c3a3-4ae7-9e16-1ba758f6962a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d27e1fdd-e23f-0d60-e053-2a95a90a9087 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9b0d279-118b-4372-bd51-d4bad9c1cfca (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3540d01c-da0e-477e-9e90-994b96deb1d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e200326-8885-18d0-e063-6294a90aad2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed264262-21bb-1bae-e053-2995a90a8a5e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85e6d64-1ddc-4f4a-86dc-0749081a6a5f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08098cb2-c048-4640-f387-6beec4a38936 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7–9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c286e5c-2b36-422b-9f74-e8c0abb3f747 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc5197e-6b39-4415-b963-d4bbeecd7953 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17468dbf-84b6-4c53-9ad5-341350d2cfab (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56ad5b97-8e5f-48a5-b2ba-a5484b43d018 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a278de-bd16-417c-a741-81bfe0d745f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e7c1ab-3e75-1ff8-e053-2995a90a7539 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b422c5eb-9a6d-4f8c-863d-ca515ec780c2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7418f358-f536-4de6-adf0-562b4373f2e3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f2fb647-15bc-41cb-84a4-02e956e614fc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138b30cb-6b28-450e-9e7a-42576cc76545 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbec80c-b38d-122c-e054-00144ff88e88 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9f32edf-e0b9-4e96-e053-2a95a90afbc8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4136d983-75fa-9604-e063-6294a90aaac6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9fa8381-b75e-b1cd-e053-2a95a90a9883 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a1af50-a051-3e55-e053-2a95a90a9184 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5ed424-2203-482f-bb85-2c97d9c356f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:564709e8-358f-c185-4ecb-b3849c3fe59c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbab54-9f11-77bc-e063-6394a90ab449 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566b4b1-b4f5-4020-e063-6394a90a5257 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8fa326-ad75-4b6d-8832-0a2357eeca2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a6b13f-457f-4136-9541-c4adb9c3c35c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9bc288b-e84c-4e31-a769-c87a59226086 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410d5577-e50a-44f3-aaa8-fbf391a0c261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51033ddc-a11a-80fa-e063-6394a90ac54c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549da3e8-f223-2ee7-e063-6394a90a25d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0bb76bc-094a-4d61-9bb2-2226c9da4ae9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17e4a72-d6a4-4a83-a921-88af9ef028a6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd4759ac-46b5-6903-e053-2a95a90a6319 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924a80b9-de48-90c0-e053-2995a90a00e1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9e3c6-d4b0-0ebe-e053-2995a90abe55 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff83f9-7039-ac26-e063-6394a90a37ce (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da67e1c0-9947-957d-e053-2a95a90ad96d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a1159d3-b9fa-4026-962c-d3001002e610 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:558dc7e1-dfd5-d3d7-e063-6394a90ab9c3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14e2f3-625d-4089-a404-440b0ecf72e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff3cf6c-6f0a-4374-8b80-4e1eb1df6245 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6aae78e-308b-7072-e053-2a95a90aaa10 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1eb666a-120d-47fd-8c9f-73cef839294a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7705bf6-e473-4b9c-bb5d-57e26ffe7b97 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac1642-6cb0-6ad2-e053-2a95a90a4cbd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fc6326-cfe6-7d1c-e063-6394a90abc24 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6229247e-ee15-466e-a8ac-adcd646b738d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c983da1-a8e0-479e-8816-5d5668ea242e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f37929-a981-4ace-95e6-ae6795a797b3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f313159c-115a-4cf6-b32e-9ddc833fd51c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3ded82a-cf0d-4844-944a-75f9f9215ff0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485212d4-caee-4a55-8299-87a28d6bd8f0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6278c0-d8c0-417c-a65c-b522ff76fe44 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f711d8-b9d3-46a6-8bf9-6af1cc77003e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f408cf-1b3e-4d7a-e053-2a95a90a369f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cec41e-e98b-470a-8ba2-c31537023989 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcac4022-fea1-67c5-3331-fefcc3c440d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8eed8c-f5d0-4b90-b184-cff8d9c8fb6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5331f534-4724-52e8-e063-6394a90aa548 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58c376e-616b-4970-a375-52ff630e7f09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d03491f-20c6-4878-9741-2e21e221eff2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d51104d-b135-421f-8425-03b5772e7103 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e9c12-e39d-4b0b-bd4c-10d3e9a4cf34 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dc4321-331d-49af-976c-cfd69d0055d9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38353b9e-63bd-47e8-b7cb-b198d1e901f9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2abc159-e450-99dc-e053-2a95a90abe6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617bb464-5357-472f-8e9d-61aae5b2ebef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3277cb8-26d0-bce0-e053-2a95a90af6dd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a969c3-1144-4151-9cf3-3e9bace6a380 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7‑fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd035d0-529c-6033-e053-6294a90abf07 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9deb251-96d3-5f96-e053-2a95a90a0792 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637d90b-b268-4a5f-ab5b-885f2d5f0d4b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1cbf26-d379-4315-8732-3939968f32c0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7-9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aa55ec-5e0e-3a58-e053-2a95a90abe4f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f38a6df2-1dd4-48bf-9ec4-1113ce492e78 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f403c94d-68b7-43df-8c8e-c9fef3309cfc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff15c4f1-8869-4422-9631-dc488e09e583 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce2e97a-cd92-46b9-9444-91739bdcd526 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ba58cc-e4ef-4b82-a0f3-9583fa123a38 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f0103a-2b97-d210-6d7d-c627d60ad694 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5 to 7 fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c46140c-2399-5ca3-e063-6394a90af33b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fbf3b5-ddf4-4d3a-8b69-a0c38b3fa5e2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89a5396-1d94-c7fa-e053-2995a90a9063 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:440b9ae8-2fb8-5d35-e063-6294a90a82b6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a94a37-47c1-4dd9-9e4d-5b4a03480aa6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de419aa0-caa9-40fb-bc6d-e341c94273c7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03dea010-4bae-43ab-893e-9bbddb58062d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9daa1483-5a36-44db-9e0d-904d100da262 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 to 9 hours and AUC values increased by 5- to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
3.5 to 10 hours
- Numeric value
- 3.5
- Unit
- hours
- Source records
- 26
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 26 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9e5fac6-2db6-4311-a98b-eb3f0dde19d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:340b57c2-bcf8-4f46-b522-886daaf80351 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb3f58d4-0c69-4377-be45-c36099c98d33 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1172bc4e-1700-402f-8262-97f05bac0d09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02ee7ed6-217f-4128-bbbb-b9390475a65b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d5bc28-66df-43aa-bb1a-8ac4a2a7f693 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014f9762-6948-46b7-8659-5c89f35ad8bf (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0696b10c-972b-9dcf-e063-6294a90a1034 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50802e19-72d3-4130-8d14-eb94361b38e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e102c44-232b-4aaf-b457-2a740c47193a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13c337e7-1e7b-47bd-9f88-92b0d548ca9c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f39b3e7d-39d2-4c8a-9974-4ab885241880 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c857dc41-7b47-4f26-a9f5-d76eb82b44ee (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb94d3c-8bc3-4193-9dd8-e9a22066707c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02f3f85-8f9b-4d06-8eae-73e592626f3e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ba4c797-3f97-4d85-971e-7b17bdf89221 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fcf6a2-3788-4955-84d9-3c319b13267c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362229c5-7b28-4563-aa62-d97d06005480 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51e4144a-489e-436c-609a-39305f8f56ba (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b71a1d-87f8-43ba-b53d-53ca3f70c63e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0c5dac-6832-4692-b012-ca59d5e88987 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bed093a-9586-4c82-a2b7-c68f89d0faef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ad8f91-3783-4139-8154-e461a53809c1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c18aff31-f91e-4b6a-9713-52c9094c6082 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c39be14b-e881-4586-b77e-4747db494954 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although these sub-populations of slow pantoprazole metabolizers have elimination half-life values from 3.5 to 10 hours, they still have minimal accumulation (23% or less) with once daily dosing.
7 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423dac8b-bb1e-4456-9b6e-913c028b11bc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 hours to 9 hours and AUC values increased by 5-fold to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90963a38-f629-45a4-bddd-9e13a55fe0f7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Although serum half-life values increased to 7 hours to 9 hours and AUC values increased by 5-fold to 7-fold in hepatic-impaired patients, these increases were no greater than those observed in CYP2C19 poor metabolizers, where no dosage adjustment is warranted.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1160Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.